Condition: Migraine · Sponsor: AEON Biopharma, Inc.
This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 765 patients across approximately 64 sites in the United States, Canada and Australia. Study subjects will be divided evenly across a low dose group, a high dose group and a placebo group. All patients will receive two treatment cycles of ABP-450 or placebo utilizing the Company's novel injection paradigm.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| MDFirst Research | Chandler, Arizona, United States | — |
| Elite Clinical Studies, LLC | Phoenix, Arizona, United States | — |
| Arizona Neuroscience Research | Phoenix, Arizona, United States | — |
| Clinical Research Consortium Arizona | Tempe, Arizona, United States | — |
| Axiom Research LLC | Colton, California, United States | — |
| Velocity Research San Diego | La Mesa, California, United States | — |
| Collaborative Neuroscience Research | Long Beach, California, United States | — |
| Los Angeles Headache Center | Los Angeles, California, United States | — |
| Anderson Clinical Research | Redlands, California, United States | — |
| Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS | San Diego, California, United States | — |
| Delta Waves LLC - Hunt - PPDS | Colorado Springs, Colorado, United States | — |
| Paradigm Clinical Research Centers | Wheat Ridge, Colorado, United States | — |
+ 50 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04845178